The report is based on milestone payments from Eisai! Another milestone coming soon. The company hasn't sold 1 pill yet! This report is only released because this is a public company and is required by SEC regulations. Until the DEA final ok, there will be no real revenues. But when the sales finally begin, a Blockbuster is born!!! Buy on the dips...
". The revenue increase in the full year ended December 31, 2012, was primarily due to the $20.0 million milestone payment from Eisai for the inclusion of the efficacy and safety data from the Phase 3 BLOOM-DM (Behavioral modification and Lorcaserin for O verweight and Obesity Management in Diabetes Mellitus) clinical trial in the FDA-approved prescribing information for Belviq."
Sentiment: Strong Buy
Absolutely, couldn't agree more. These numbers mean absolutely, absolutely nothing. Selloff this morning was nothing more than a bear raid, HF's knowing that a large percentage is in retail hands, thusly know that many have not done proper DD and thusly can be scared out.
Missed who's estimates? Some ANAL-YST that expected sales of the drug by now? And when was their estimate made? This is so bogus! An estimate based on sales that haven't begun yet??? A great buy here...
Sentiment: Strong Buy
I don't get this sell off... it's rediculous. ARENA is on the "eve" of launching B, what in the world are the retail's thinking? of course we were going to miss estimates without the 65mil final DEA benchmark from Elsai. we have no way to generate $$ without either making deals or selling inventory. f'n lemmings. for sure i'm going to buy at this level.
Sentiment: Buy
Of course, nothing of substance has changed. Belviq will still get the DEA schedule very very
soon, and probably sell fairly well. This is really a yawn kinda day for long stock holders of ARNA
(who can't buy more) and somewhat exciting for those that can! Me included as a buyer!
Sentiment: Strong Buy
missed earnings doesn't mean anything?,,,lol
THERE ARE NO EARNINGS YET!!! GET THAT THROUGH YOUR HEADS PEOPLE!!! This quarterly report is required by the SEC, earnings or no earnings! The estimates are from ANALysts that thought B would already be on the shelves!
Sentiment: Strong Buy
Missed earnings means NOTHING based on where this company is! Nothing! It's a bio burning cash until they sell drug or do further deals.
JMO
Kutz
Sentiment: Strong Buy